We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+32.6%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.65B
AUM Growth
+$1.82B
Cap. Flow
+$94.6M
Cap. Flow %
0.98%
Top 10 Hldgs %
77.89%
Holding
99
New
5
Increased
16
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$37.7M
3
IMVT icon
Immunovant
IMVT
+$22.4M
4
BCAX
Bicara Therapeutics
BCAX
+$21.3M
5
SMMT icon
Summit Therapeutics
SMMT
+$16.8M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$28M
2
LONA
LeonaBio Inc
LONA
+$8.36M
3
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$4.4M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$2.28M
5
SAGE
Sage Therapeutics
SAGE
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 98.95%
2 Miscellaneous 1.02%
3 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
51
Arvinas
ARVN
$540M
$9.99M 0.1%
+405,576
New +$10.6M
SANA icon
52
Sana Biotechnology
SANA
$946M
$9.9M 0.1%
2,380,949
– –
DSGN icon
53
Design Therapeutics
DSGN
$765M
$9.38M 0.1%
1,743,725
+48,431
+3% +$228K
IONS icon
54
Ionis Pharmaceuticals
IONS
$7.85B
$8.95M 0.09%
+223,470
New +$10.4M
OPT
55
DELISTED
Opthea Limited American Depositary Shares
OPT
$8.85M 0.09%
2,173,622
– –
CLDX icon
56
Celldex Therapeutics
CLDX
$3.02B
$8.42M 0.09%
247,644
– –
RLAY icon
57
Relay Therapeutics
RLAY
$4.16B
$8.21M 0.09%
1,160,117
– –
VERV
58
DELISTED
Verve Therapeutics
VERV
$8.19M 0.08%
1,691,530
– –
TSHA icon
59
Taysha Gene Therapies
TSHA
$1.65B
$8.05M 0.08%
4,004,756
– –
MIRM icon
60
Mirum Pharmaceuticals
MIRM
$6.1B
$7.43M 0.08%
190,476
– –
CTNM
61
Contineum Therapeutics
CTNM
$520M
$5.98M 0.06%
312,500
– –
TNGX icon
62
Tango Therapeutics
TNGX
$4.03B
$5.78M 0.06%
750,000
– –
SKYE icon
63
Skye Bioscience
SKYE
$9.34M
$5.61M 0.06%
179,329
+116,829
+187% +$5.24M
PCVX icon
64
Vaxcyte
PCVX
$8.81B
$5.59M 0.06%
48,885
– –
CRNX
65
DELISTED
Crinetics Pharmaceuticals
CRNX
$5.31M 0.06%
103,927
– –
DBVT
66
DBV Technologies
DBVT
$739M
$5.11M 0.05%
1,461,426
– –
KALA icon
67
KALA BIO
KALA
$9.82M
$5.08M 0.05%
17,827
– –
GBIO
68
DELISTED
Generation Bio
GBIO
$4.8M 0.05%
194,495
+73,799
+61% +$1.95M
ALEC icon
69
Alector
ALEC
$228M
$4.32M 0.04%
927,264
– –
PRME icon
70
Prime Medicine
PRME
$570M
$3.98M 0.04%
1,028,466
– –
SGMT icon
71
Sagimet Biosciences
SGMT
$650M
$3.83M 0.04%
1,381,898
– –
GPCR icon
72
Structure Therapeutics
GPCR
$2.78B
$3.75M 0.04%
+85,500
New +$3.31M
ARCT icon
73
Arcturus Therapeutics
ARCT
$450M
$3.51M 0.04%
151,329
– –
HOOK
74
DELISTED
HOOKIPA Pharma
HOOK
$3.5M 0.04%
812,814
-1
-0% -$5
CYPH
75
Cypherpunk Technologies Inc
CYPH
$239M
$3.01M 0.03%
1,172,175
– –
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Baker Bros. Advisors held 99 positions worth $9.65B, up 23% from $7.83B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Baker Bros. Advisors's Q3 2024 filing shows 5 new, 16 increased, 3 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 833,333 shares worth $21.2M. The largest sale was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q3 2024 buy was Bicara Therapeutics: 833,333 shares worth $21.2M.
  • Baker Bros. Advisors added most to Insmed in Q3 2024, an estimated $62M increase.
  • Baker Bros. Advisors's biggest Q3 2024 reduction was NewAmsterdam Pharma, cutting an estimated $2.01K.
  • Baker Bros. Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $28M.
  • Baker Bros. Advisors's ten largest holdings make up 78% of its $9.65B portfolio in Q3 2024.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q3 2024.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.65B.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.